Skip to content

Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Frozen Shoulder

Ultrasound Guided Continuous Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Patients With Frozen Shoulder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05037994
Enrollment
40
Registered
2021-09-08
Start date
2021-04-01
Completion date
2021-10-30
Last updated
2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Shoulder

Brief summary

The patients will be randomly allocated into two equal groups (each 20 patients) using sealed opaque numbered envelopes: Control Group (C Group) : Patients receive continuous US suprascapular nerve block only. Gabapentin Group (G Group) : Patients receive continuous US suprascapular nerve block with oral gabapentin 300 mg once daily at bed time. Both groups compared as regard: Visual Analogue Scale Range of passive and active movements Patients satisfaction complication related to block The total dose of diclofenac sodium

Interventions

PROCEDUREUltrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine

The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine. Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap.

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index ≥ 18 Kg/m2 ≤ 30Kg/m2 * ASA I, II or III. * Cooperative patients.

Exclusion criteria

* local infection at site of injection. * coagulopathy * previous history of mental disorders or chronic drug abuse (opioids, tranquilizers) * known hypersensitivity to any of the drugs used in the study.

Design outcomes

Primary

MeasureTime frameDescription
Visual analogue scale6 weeks10cm line where zero means no pain and ten means worse imaginary pain

Secondary

MeasureTime frameDescription
Range of passive and active movements6 weeksby goniometer
Patients satisfaction6 weeksby questionnaire with 3 degrees 1. Fair 2. Good 3. Excellent

Other

MeasureTime frameDescription
The total dose of diclofenac sodium6 weeksIndicator for analgesia required

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026